Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Catalyst Pharmaceuticals Announces First Quarter 2021 Financial Results and Provides Business Update
Catalyst Pharmaceuticals, Inc.May 10, 2021 GMT
-Firdapse® Q1 2021 Net Revenues of $30.2 Million
-First Quarter 2021 GAAP Net Income of $7.7 Million; Non-GAAP Net Income of $11.6 Million
-Recently Received Orphan Drug Designation for Firdapse® in Japan
-$143.3 Million in Cash and Investments and no Funded Debt at end of Q1-2021
-Catalyst to Host Quarterly Conference Call at 8:30 AM ET Tomorrow
CORAL GABLES, Fla., May 10, 2021 (GLOBE NEWSWIRE) Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases, today reported financial results for the first quarter ended March 31, 2021 and provided a business